Want to join the conversation?
$ALXN reported today that its Biologics License Application (BLA) for Kanuma, an investigational enzyme replacement therapy for the treatment of lysosomal acid lipase deficiency, has received a PDUFA date extension from the FDA. It has got 3 months extension from the earlier reported Sept. 8, 2015 PDUFA date, and reiterating its guidance for 2015.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.